TNF and tuberculosis: Although these small molecules have better safety and lower production costs than existing drugs, long-term clinical trials have shown that: TNF inhibitors are associated with an increased risk of infection, especially early in the course of treatment, which puts patients with RA at a higher risk of disease (including tuberculosis) after using these drugs (19).